Efficacy of Strontium Ranelate in Combination with a D-Hormone Analog for the Treatment of Postmenopausal Osteoporosis

Drugs in R and D

Volumn 14, Issue 4, 2014, Pages 315-324

  Abboskhujaeva, Lola S ^a,b   Ismailov, Saydiganikhodja I ^a,b   Alikhanova, Nodira M ^a,b  

^a The Center for the Scientific and Clinical Study of Endocrinology   (Uzbekistan)

^b Republican Scientific Center of Immunology   (Uzbekistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; BIOLOGICAL MARKER; CALCIUM; COLECALCIFEROL; PROCOLLAGEN; PROCOLLAGEN TYPE 1; STRONTIUM RANELATE; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; COLLAGEN; GLUTAMYL-LYSYL-ALANYL-HISTIDYL-ASPARTYL-GLYCYL-GLYCYL-ARGININE; HYDROXYCOLECALCIFEROL; PEPTIDE FRAGMENT; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPEPSIA; FALL RISK ASSESSMENT; FEMALE; FEMUR; FUNCTIONAL ASSESSMENT; HUMAN; HYPERTENSION; LUMBAR SPINE; MIDDLE AGED; MONOTHERAPY; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; BLOOD; BONE; COMBINATION DRUG THERAPY; DRUG EFFECTS; FALLING; METABOLISM; MOTOR PERFORMANCE; OSTEOPOROSIS, POSTMENOPAUSAL;

ACCIDENTAL FALLS; AGED; BIOMARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; MIDDLE AGED; MOTOR SKILLS; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PROCOLLAGEN; THIOPHENES;

EID: 84919421740     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-014-0069-1     Document Type: Article

References (53)

1. Toroptsova NV, Nikitinskaya OA, Demin NV, Benevolenskaya LI. Prevention of post-menopausal osteoporosis, results of three-year observation (in Russian). Sci Pract Rheumatol. 2006;5:25–32.
2. Barrett-Connor E. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res. 2005;33:19–24.
3. Cauley J. Prevalent vertebral fractures in black women and white women. J Bone Miner Res. 2008;23(9):1458–67.
4. Lansdown D, Bennet B, Thiel S, Ahmed O, Dixon L, Vokes T. Prevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women. Osteoporos Int. 2011;22(8):2365–71.
5. Kandiloytu AYu. Osteopenic syndrome in per-menopausal female residents of Tashkent, its correction. Author’s abstract for Candidate of Science Thesis (in Russian). Tashkent; 2005. p. 24.
6. Ershova OB, Belova KYu, Ganert OA, Nazarova AV, Romanova MA, Sinitsyna OS. Arrangement of care for osteoporotic patients with proximal hip fractures (in Russian). Russ Med J. 2010;27:38–42.
7. Jarvinen T, Sievanen H, Khan K, Heinonen A, Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. Br Med J. 2008;336:124–6.
8. Kannus P. Why is the age-standardized incidence of low-trauma fractures rising in many elderly populations? J Bone Miner Res. 2002;17:1363–7.
9. Kannus P, Sievanen H, Palvanen M, Jarvinen T, Parkkari J. Prevention of falls and consequent injuries in elderly people. Lancet. 2005;366:1885–93.
10. Dukas L, Schacht E, Mazor Z, Stahelin H. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of < 65 ml/min. Osteoporos Int. 2005;16:198–203.
11. Bischoff H, Borchers M, Gudat F, et al. In situ detection of 1.25-dihydroxyvitamin D receptor in human skeletal muscle tissue. Histochem J. 2001;33:19–24.
12. Belaya JE, Rojinskaya LYa. Falls as a significant social problem among elders. Basic mechanisms of its onset and progression and ways for prevention (in Russian). Russ Med J. 2009;24:28–34.
13. Maki B, Mcllroy W. Control of rapid limb movements for balance recovery: age-related changed and implications for fall prevention. Age Ageing. 2006;35(Suppl 2):12–8.
14. Boland R. Role of vitamin D in skeletal muscle function. Endocr Rev. 1986;784:434–48.
15. Schacht E, Richy F, Reginster J-Y. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact. 2005;5(3):273–84.
16. 3 analogues: a review with meta-analysis of randomized controlled trails including organ transplantation studies. Osteoporos Int. 2004;15(8):589–602.
17. Dukas L, Bischoff HA, Lindpaintner LS, et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc. 2004;52:230–6.
18. Dukas L, Schacht E, Bischoff H. Better functional mobility in community dwelling elderly is related to D hormone serum levels and to daily calcium intake. J Nutr Health Aging. 2005;9(5):347–51.
19. Richy F, Ethgen O, Bruyere O. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int. 2005;76:176–86.
20. Richy F, Dukas L, Schacht E. Differential effects of D hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif Tissue Int. 2008;82(2):102–7.
21. Dukas L, Schacht E, Runge M, Ringe J. Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls. Arzneimittelforschung. 2010;60:519–25.
22. Rizzoli R, Boonen S, Brandi ML, et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin. 2013;29(4):305–13.
23. Chel V, Wijnhoven H, Smit J, Ooms M, Lips P. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int. 2008;19(5):663–71.
24. Rojinskaya LYa, Belyaeva AV, Belaya JE. Strontium ranelate (Bivalos)—a medication with two-sided effect on bone tissue; novel approaches to treatment of osteoporosis. Osteoporos Osteopenia. 2006;1:34–43.
25. Skripnikova IA, Poddubskaya EA, Kosmatova OV, et al. Usage of Bivalos (strontium ranelate) in post-menopausal osteoporosis (in Russian). Sci Pract Rheumatol. 2009;2:43–8.
26. Podsialdo D, Richardson S. The timed “up and go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.
27. Mathias S, Nayak U, Isaacs B. Balance in elderly patients: the “get-up and go” test. Arch Phys Med Rehabil. 1986;67:387–9.
28. Zhu K, Devine A, Lewis JR, Dhaliwal SS, Prince RL. Timed ‘up and go’ test and bone mineral density measurements for fracture prevention. Arch Intern Med. 2011;171:1655–61.
29. Gill T, Williams C, Tinetti M. Assessing risk for the onset of functional dependence among older adults: the role of physical performance. J Am Geriatr Soc. 1995;43:603–9.
30. Runge M, Rehfeld G, Resnicek E. Balance training and exercise in geriatric patients. J Musculoskelet Neuronal Interact. 2000;1:54–8.
31. Verhaar H, Samson M, Jansen P, et al. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res. 2000;12:268–74.
32. Ammann P. Strontium ranelate: a novel mode of action leading to renewed bone quality. Osteoporos Int. 2005;16:11–6.
33. Blake G, Foglman I. Long-term effect of strontium ranelate on BMD. J Bone Miner Res. 2005;20:190–4.
34. Buehler J, Chappuis P, Saffar J. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in moneys (Macaca fascicularis). Bone. 2001;29:176–9.
35. Povoroznyuk VV, Dzerovich NI, Orlik TV, Vaida VM. Effect of strontium ranelate on bone mineral density and vertebral pain syndrome in post-menopausal women: literature data and the authors’ studies. Probl Osteol (Ukraine). 2008;11(1–2):15–24.
36. O’Donnel S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev. 2006;3:CD005326.
37. Meunier P, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459–68.
38. Reginster J, Deroisy R, Dougados M, et al. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled (PREVOS) trial. Osteoporos Int. 2002;13:925–31.
39. Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res. 2006;21:1113–20.
40. Reginster J, Seeman E, De Vernejoul M, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816–22.
41. Bruyere O, Roux C, Badurski J, Isaia G, De Vernejoul MC, Cannata J, et al. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin. 2007;23:3041–5.
42. Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab. 2007;92:3076–81.
43. Rizzoli R, Dawson-Huges B, Kaufman J-M, et al. Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients. Eur J Endocrinol. 2014;170:441–50.
44. Rizzoli R, Dawson-Hughes B, Kaufman JM, Fardellone P, Brandi ML, Vellas B, Collette J, Reginster JY. Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients. Eur J Endocrinol. 2014;170:441–50.
45. Bischoff-Ferrari H, Willett W, Wong J, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169(6):551–61.
46. Guralnik J, Ferrucci L, Simonsick E, Salive M, Wallace R. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556–61.
47. Ito S, Harada A, Kasai T, Sakai Y, Takemura M, Matsui Y, Hida T, Ishiguro N. Use of alfacalcidol in osteoporotic patients with low muscle mass might increase muscle mass: an investigation using a patient database. Geriatr Gerontol Int. 2014;14(Suppl 1):122–8.
48. Dukas L, Schacht E, Runge M, Ringe JD. Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls. Arzneimittelforschung. 2010;60:519–25.
49. Nordin B, Need A, Morris H, Horowitz M. The special role of “hormonal” forms of vitamin D in the treatment of osteoporosis. Calcif Tissue Int. 1999;65:307–10.
50. Lau K, Baylink D. Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D hormone) therapy. Calcif Tissue Int. 1999;65:295–306.
51. Richy F, Ethgen O, Bruyere O. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004;15(4):301–10.
52. Delmas P, Eastell R, Garnero P, Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int. 2000;6:2–17.
53. Kostyuchek DF, Dushenkova TA, Rischuk SV. Early diagnosis of osteoporosis in pre- and post-menopausal women (in Russian). J Obstet Women Dis. 2006;55(1):3–7.